HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its first quarter 2022 financial results on May 16, 2022, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its first quarter 2022 financial results on May 16, 2022, before the market opens. The company specializes in developing novel immunotherapies using its proprietary arenavirus platform to enhance T cell responses against serious diseases. HOOKIPA's pipeline focuses on investigational immunotherapeutics targeting various cancers and aims to develop functional cures for HBV and HIV in partnership with Gilead. No conference call will accompany the earnings release.
Positive
- Development of unique immunotherapies targeting various cancers.
- Collaboration with Gilead for HBV and HIV solutions.
Negative
- No conference call to discuss the earnings, limiting investor engagement.
Details
News Market Reaction – HOOK
The recorded move for HOOK in the trading session of this news was -8.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.
The Company will not be conducting a conference call in conjunction with this earnings release.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
| Media | Investors | |
| Instinctif Partners | Matt Beck | |
| hookipa@instinctif.com | Executive Director – Investor Relations | |
| +44 (0)20 7457 2020 | matthew.beck@hookipapharma.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.